Lyell Immunopharma (LYEL) AI Stock Analysis

• Market Cap: $144.23M
• Dividend Yield: N/A
• Average Volume (3M): 162.57K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.93
• Revenue Growth: -4.41%
• EPS Growth: -38.08%
• Country: US
• Employees: 300
• Sector: Healthcare
• Sector Strength: 58
• Industry: Biotechnology
• EPS (TTM): -3.54
• Shares Outstanding: 14,808,078
• 10 Day Avg. Volume: 429,298
• 30 Day Avg. Volume: 162,571
• PEG Ratio: -0.08
• Price to Book (P/B): 0.36
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.69
• Enterprise Value/Market Cap: 0.34
• Enterprise Value/Revenue: 204.16
• Enterprise Value/Gross Profit: 763.26
• Enterprise Value/Ebitda: -0.06
• 1Y Price Target: $16.00
• Price Target Upside: 64.27% Upside
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 3

• Rating: 55 Neutral
• Price Target: $9.50 ▼(-2.46%Downside)

Lyell Immunopharma's stock is facing significant challenges primarily due to its financial performance, characterized by zero revenue and ongoing losses. Technical analysis shows neutral to slightly positive indicators, but valuation remains a concern due to negative earnings. The absence of earnings call data and corporate events limits additional insights into the company's strategic direction.

Positive Factors

FDA Communication

RMAT designation enables increased frequency of FDA communications on LYL314 development.

Financial Stability

Lyell ended 4Q24 with $383.5 million in cash, which management expects to provide an operational runway into 2027.

Negative Factors

Earnings

Lyell reported a net loss of $0.69 per share, which was worse than the analyst's estimate of a net loss of $0.18 per share.

Market Competition

The CD19-targeted CAR-T space is considered crowded and may not support another entrant with the current under $3 billion aggregated annual sales across competitors.

Strategic Uncertainty

The decision to discontinue next-gen, early-stage, solid tumor CAR-T LYL119 adds to the uncertainty surrounding Lyell's strategy.

Lyell Immunopharma Business Overview & Revenue Model

Company Description

Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

How the Company Makes Money

Lyell Immunopharma generates revenue primarily through strategic collaborations and partnerships with pharmaceutical and biotechnology companies. These partnerships often involve licensing agreements, milestone payments, and royalties associated with the development and commercialization of T-cell therapies. Additionally, Lyell may receive funding from grants and research collaborations aimed at advancing their scientific innovations. The company also invests in developing proprietary technologies and seeks to monetize these innovations through clinical success, leading to potential product sales and additional partnerships.

Lyell Immunopharma Financial Statement Overview

Summary

Lyell Immunopharma is facing substantial financial challenges, primarily due to its inability to generate revenue and persistent operational losses. The balance sheet is relatively stronger, with a manageable level of debt and a good equity base. However, the company's cash flow situation is strained, with heavy reliance on financing for liquidity. Overall, the financial position reflects high operational risk and the need for strategic shifts to improve revenue and profitability.

Income Statement

Lyell Immunopharma has faced significant challenges in revenue generation, with revenue dropping to zero in the latest year. The company has consistently reported negative net income, resulting in negative net profit margins. The absence of revenue and persistent losses indicate financial difficulties in scaling operations or commercializing products.

Balance Sheet

The balance sheet shows a strong equity position with a low debt-to-equity ratio, reflecting financial prudence. However, the decline in stockholders' equity over the years may indicate operational challenges. The equity ratio remains healthy, suggesting solid capital management despite operational losses.

Cash Flow

Lyell Immunopharma's cash flow statement highlights significant operating cash outflows due to ongoing losses. While free cash flow remains negative, the company has maintained a consistent level of cash reserves. The ability to generate positive cash flow from financing activities has been crucial in sustaining operations.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
65.00K	61.00K	130.00K	84.68M	10.65M	7.76M
	Gross Profit
65.00K	61.00K	130.00K	68.22M	-3.88M	281.00K
	EBIT
-360.55M	-358.75M	-247.01M	-183.12M	-214.78M	-211.94M
	EBITDA
-204.02M	-200.64M	-226.76M	-166.65M	-199.94M	-207.64M
	Net Income Common Stockholders
-334.52M	-342.99M	-234.63M	-4.75M	-285.50M	-198.53M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
526.30M	370.53M	546.22M	640.15M	614.79M	612.62M
	Total Assets
694.22M	490.86M	750.03M	937.56M	1.13B	908.28M
	Total Debt
61.83M	58.97M	63.17M	67.70M	67.82M	54.57M
	Net Debt
-63.82M	-46.63M	-82.48M	-55.85M	-226.01M	-85.83M
	Total Liabilities
91.06M	108.03M	95.08M	104.31M	197.62M	189.84M
	Stockholders Equity
603.16M	382.82M	654.95M	833.25M	929.79M	718.44M
Cash Flow		Free Cash Flow
-175.80M	-162.86M	-166.38M	-193.83M	-191.75M	-212.35M
	Operating Cash Flow
-175.12M	-162.39M	-163.69M	-169.56M	-126.25M	-160.87M
	Investing Cash Flow
169.90M	122.42M	184.05M	-11.54M	-121.57M	-273.52M
	Financing Cash Flow
1.30M	1.33M	1.74M	10.63M	401.24M	476.79M

Lyell Immunopharma Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 9.74
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LYEL, the sentiment is Negative. The current price of 9.74 is above the 20-day moving average (MA) of 9.46, above the 50-day MA of 9.04, and below the 200-day MA of 15.63, indicating a neutral trend. The MACD of 0.45 indicates Negative momentum. The RSI at 50.46 is Neutral, neither overbought nor oversold. The STOCH value of 31.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LYEL.

Lyell Immunopharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ADCT	58 Neutral	$363.98M	―	123.38%	―	10.49%	47.31%
SEER	57 Neutral	$125.34M	―	-24.73%	―	-1.02%	-8.59%
LYEL	55 Neutral	$144.23M	―	-71.20%	―	-4.41%	-38.08%
Sector *	54 Neutral	$5.41B	3.27	-45.10%	3.29%	16.81%	0.02%
FDMT	48 Neutral	$208.46M	―	-32.97%	―	―	―
FATE	45 Neutral	$160.49M	―	-49.23%	―	105.85%	22.13%
NKTX	39 Underperform	$141.92M	―	-26.10%	―	―	30.76%

Lyell Immunopharma Corporate Events

Lyell Immunopharma Expands Board, Appoints New Director

On June 9, 2025, Lyell Immunopharma‘s Board of Directors expanded from seven to eight members, appointing Mark Bachleda, Pharm.D., M.B.A., as a Class I director. Dr. Bachleda will serve until the 2028 annual stockholders meeting, receiving compensation and equity grants as per the company’s policy, adjusted for a recent reverse stock split.

The most recent analyst rating on (LYEL) stock is a Hold with a $80.00 price target. To see the full list of analyst forecasts on Lyell Immunopharma stock, see the LYEL Stock Forecast page.

Lyell Immunopharma Announces 1-for-20 Reverse Stock Split

On May 27, 2025, Lyell Immunopharma announced a reverse stock split at a 1-for-20 ratio, authorized by its stockholders during the annual meeting on May 15, 2025. Effective May 30, 2025, this move will consolidate every 20 shares into one, adjusting stock options and equity plans proportionately, with trading on a split-adjusted basis starting June 2, 2025, on Nasdaq. This action aims to streamline the company’s stock structure without altering shareholders’ proportional ownership.

The most recent analyst rating on (LYEL) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Lyell Immunopharma stock, see the LYEL Stock Forecast page.

Lyell Immunopharma Stockholders Approve Key Proposals

On May 15, 2025, Lyell Immunopharma held its annual meeting of stockholders virtually, with 71.9% of shares represented, constituting a quorum. Stockholders voted on four proposals, including the election of Catherine Friedman as a director, ratification of Ernst & Young LLP as auditors, approval of executive compensation, and potential reverse stock split amendments, all of which were passed.

The most recent analyst rating on (LYEL) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Lyell Immunopharma stock, see the LYEL Stock Forecast page.

Lyell Immunopharma’s LyFE Center Begins IMPT-314 Production

Following FDA clearance, Lyell Immunopharma’s LyFE manufacturing center in Bothell, Washington, is now producing IMPT-314 for a Phase 1/2 clinical trial targeting relapsed/refractory aggressive large B-cell lymphoma. The company plans to close its West Hills facility, acquired in 2024, resulting in a workforce reduction of approximately 73 employees and expected costs of $3.0 million to $4.0 million. Additionally, Chief Business Officer Matthew Lang announced his resignation, effective April 13, 2025, but will remain as an advisor until September 30, 2025. Lyell maintains its financial guidance, projecting a net cash use of $175 million to $185 million in 2025, ensuring operational runway into 2027.